Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation
Background The effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrial fibrillation (AF) has remained uncertain. This study aimed to assess whether statin use could lead to better outcomes among individuals with AF. Methods and Results We enrolled 397 787 p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.124.035827 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846118663526023168 |
|---|---|
| author | Ting‐Chun Huang Li‐Hao Yap Chao‐Yu Chen Hui‐Wen Lin Sheng‐Hsiang Lin Yi‐Heng Li |
| author_facet | Ting‐Chun Huang Li‐Hao Yap Chao‐Yu Chen Hui‐Wen Lin Sheng‐Hsiang Lin Yi‐Heng Li |
| author_sort | Ting‐Chun Huang |
| collection | DOAJ |
| description | Background The effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrial fibrillation (AF) has remained uncertain. This study aimed to assess whether statin use could lead to better outcomes among individuals with AF. Methods and Results We enrolled 397 787 patients with AF from January 1, 2012 to December 31, 2020. Patients with AF were divided into 2 groups (statin user and statin nonuser), and the risks of composite outcomes (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack), all‐cause death, and major adverse cardiovascular events (which encompassed cardiovascular death, myocardial infarction, stroke, and heart failure hospitalization) were analyzed. We analyzed 288 958 patients with newly diagnosed AF (mean age, 73 years; 44% women; mean CHA2DS2‐VASc score, 3.5). Compared with patients without statin use, statin users had lower risks of composite end points (adjusted hazard ratio [HR], 0.91 [95% CI, 0.87–0.94]; P<0.01). In regard to all‐cause death, statin users exhibited a 67% risk reduction compared with statin nonusers (adjusted HR, 0.33 [95% CI, 0.32–0.33]; P<0.01). Statin use was also associated with reduced incidence of major adverse cardiovascular events (adjusted HR, 0.64 [95% CI, 0.63–0.66]; P<0.01). In the subgroups stratified by CHA2DS2‐VASc score, statin therapy was particularly effective for patients with CHA2DS2‐VASc scores 0 to 3 for composite end points but consistently reduced all‐cause mortality and major adverse cardiovascular events across all score categories. Conclusions Among patients with newly diagnosed AF, statin use was associated with lower risk of ischemic stroke, hemorrhagic stroke, transient ischemic attack, all‐cause mortality, and major adverse cardiovascular events. |
| format | Article |
| id | doaj-art-c27f542f971e4e0185bd5a4fe6f09839 |
| institution | Kabale University |
| issn | 2047-9980 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj-art-c27f542f971e4e0185bd5a4fe6f098392024-12-17T12:51:22ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802024-12-01132410.1161/JAHA.124.035827Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial FibrillationTing‐Chun Huang0Li‐Hao Yap1Chao‐Yu Chen2Hui‐Wen Lin3Sheng‐Hsiang Lin4Yi‐Heng Li5Institute of Clinical Medicine, College of Medicine National Cheng Kung University Tainan TaiwanDivision of Cardiology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan TaiwanDivision of Cardiology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan TaiwanDivision of Cardiology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan TaiwanInstitute of Clinical Medicine, College of Medicine National Cheng Kung University Tainan TaiwanDivision of Cardiology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan TaiwanBackground The effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrial fibrillation (AF) has remained uncertain. This study aimed to assess whether statin use could lead to better outcomes among individuals with AF. Methods and Results We enrolled 397 787 patients with AF from January 1, 2012 to December 31, 2020. Patients with AF were divided into 2 groups (statin user and statin nonuser), and the risks of composite outcomes (including ischemic stroke, hemorrhagic stroke, and transient ischemic attack), all‐cause death, and major adverse cardiovascular events (which encompassed cardiovascular death, myocardial infarction, stroke, and heart failure hospitalization) were analyzed. We analyzed 288 958 patients with newly diagnosed AF (mean age, 73 years; 44% women; mean CHA2DS2‐VASc score, 3.5). Compared with patients without statin use, statin users had lower risks of composite end points (adjusted hazard ratio [HR], 0.91 [95% CI, 0.87–0.94]; P<0.01). In regard to all‐cause death, statin users exhibited a 67% risk reduction compared with statin nonusers (adjusted HR, 0.33 [95% CI, 0.32–0.33]; P<0.01). Statin use was also associated with reduced incidence of major adverse cardiovascular events (adjusted HR, 0.64 [95% CI, 0.63–0.66]; P<0.01). In the subgroups stratified by CHA2DS2‐VASc score, statin therapy was particularly effective for patients with CHA2DS2‐VASc scores 0 to 3 for composite end points but consistently reduced all‐cause mortality and major adverse cardiovascular events across all score categories. Conclusions Among patients with newly diagnosed AF, statin use was associated with lower risk of ischemic stroke, hemorrhagic stroke, transient ischemic attack, all‐cause mortality, and major adverse cardiovascular events.https://www.ahajournals.org/doi/10.1161/JAHA.124.035827atrial fibrillationmyocardial infarctionstatinstroke |
| spellingShingle | Ting‐Chun Huang Li‐Hao Yap Chao‐Yu Chen Hui‐Wen Lin Sheng‐Hsiang Lin Yi‐Heng Li Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease atrial fibrillation myocardial infarction statin stroke |
| title | Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation |
| title_full | Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation |
| title_fullStr | Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation |
| title_full_unstemmed | Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation |
| title_short | Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation |
| title_sort | long term statin use is associated with reduced rates of adverse events in patients with newly diagnosed atrial fibrillation |
| topic | atrial fibrillation myocardial infarction statin stroke |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.124.035827 |
| work_keys_str_mv | AT tingchunhuang longtermstatinuseisassociatedwithreducedratesofadverseeventsinpatientswithnewlydiagnosedatrialfibrillation AT lihaoyap longtermstatinuseisassociatedwithreducedratesofadverseeventsinpatientswithnewlydiagnosedatrialfibrillation AT chaoyuchen longtermstatinuseisassociatedwithreducedratesofadverseeventsinpatientswithnewlydiagnosedatrialfibrillation AT huiwenlin longtermstatinuseisassociatedwithreducedratesofadverseeventsinpatientswithnewlydiagnosedatrialfibrillation AT shenghsianglin longtermstatinuseisassociatedwithreducedratesofadverseeventsinpatientswithnewlydiagnosedatrialfibrillation AT yihengli longtermstatinuseisassociatedwithreducedratesofadverseeventsinpatientswithnewlydiagnosedatrialfibrillation |